Clinical Trial Update: Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy [Phase 2]

View source ↗

Summary

A Phase 2 comparison of LNP023 (iptacopan) versus Rituximab in idiopathic membranous nephropathy was terminated, and results have been posted as of 2024-07-05.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Membranous Nephropathy

Drugs mentioned

• LNP023 (iptacopan) (iptacopan)
• Rituximab (rituximab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Idiopathic Membranous Nephropathy | Phase 2 | Status: TERMINATED | Results posted: 2024-07-05